Premium
Adjunctive benefits of systemic metronidazole on non‐surgical treatment of peri‐implantitis. A randomized placebo‐controlled clinical trial
Author(s) -
Blanco Carlota,
Pico Alex,
Dopico Jose,
Gándara Pilar,
Blanco Juan,
Liñares Antonio
Publication year - 2022
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/jcpe.13564
Subject(s) - medicine , metronidazole , peri implantitis , tannerella forsythia , placebo , randomized controlled trial , clinical trial , surgery , adjunctive treatment , debridement (dental) , dentistry , antibiotics , implant , pathology , microbiology and biotechnology , biology , honeysuckle , alternative medicine , traditional chinese medicine
Aim To study clinical, radiographic, and microbiological outcomes after non‐surgical therapy of peri‐implantitis with or without adjunctive systemic metronidazole. Materials and Methods A randomized placebo‐controlled clinical trial was carried out in 32 subjects (62 implants) diagnosed with peri‐implantitis. Implants received a mechanical non‐surgical debridement session and systemic metronidazole or placebo. Clinical, radiographic, and microbiological outcomes were evaluated at baseline, 3, 6, and 12 months. Results After 12 months, the test treatment resulted in significantly greater PPD reduction (2.53 vs. 1.02 mm) and CAL gain (2.14 vs. 0.53 mm) ( p value <.05) in comparison with placebo. The test treatment also resulted in additional radiographic bone gain (2.33 vs. 1.13 mm) compared with placebo ( p value <.05). There was a significantly greater decrease in Porphyromonas gingivalis , Tannerella forsythia , and Campylobacter rectus counts compared with the control group ( p value <.05). At the end of follow‐up, 56.3% of patients met the success criteria in the test group and 25% in the control group. Conclusions The use of systemic metronidazole as an adjunct to non‐surgical treatment of peri‐implantitis resulted in significant additional improvements in clinical, radiographic, and microbiological parameters after 12 months of follow‐up. This study is registered in ClinicalTrials.gov (NCT03564301).